Table 2 Clinical and laboratory characteristics in patients with YOFMF, AOFMF, and LOFMF (univariate analyses)

Frequency of febrile attack (/month)^a

1.0 (0.3–1.0, n = 157)

1.0 (0.4–1.0, n = 97)

0.5 (0.4–1.0, n = 74)

Duration of fever attack (days)^a

2.5 (2–4, n = 165)

3 (2–4.8, n = 101)

2.5 (2–5, n = 71)

Headache

25/161 (16%)

18/91 (20%)

10/65 (15%)

Thoracic pain

82/182 (45%)

38/115 (33%)

22/90 (24%)

Abdominal pain

117/182 (64%)

64/115 (56%)

27/90 (30%)

Pericarditis

3/161 (2%)

3/91 (3%)

4/65 (6%)

Arthritis

58/182 (32%)

55/115 (48%)

56/90 (62%)

Myalgia

13/161 (8%)

16/91 (18%)

17/65 (26%)

Erysipelas-like erythema

18/182 (10%)

16/115 (14%)

17/90 (19%)

Good response to colchicine

124/126 (98%)

85/87 (98%)

69/71 (97%)

WBC (× 10³/μl)^a

10 (7.2–13, n = 126)

9.1 (7.2–12.5, n = 64)

9.1 (7.4–12, n = 48)

CRP (mg/dl)^a

7.1 (4.0–12.7, n = 132)

7.1 (2.1–11.1, n = 65)

9.4 (3.4–15, n = 50)

SAA (μg/ml)^a

85 (206–1246, n = 43)

423 (55–1100, n = 13)

300 (105–702, n = 9)

ESR (mm/h)^a

40 (24–51, n = 39)

41.5 (15.5–56, n = 10)

56 (35–90, n = 15)

IgD (mg/dl)^a

4.2 (1.1–10.9, n = 17)

1.5 (1.0–2.3, n = 3)

10 (1.9–18, n = 2)